0300293160208

BEECHAM LABORATORIES 100 8 mg tabs Avandia Rosiglitazone Tablets

300293160208

About this product

Written automatically from public information, so it may contain mistakes.

I've searched for information on the barcode 300293160208 reported as BEECHAM LABORATORIES 100 8 mg tabs Avandia Rosiglitazone Tablets.

The product is indeed a brand-name medication, specifically an oral antidiabetic drug belonging to the thiazolidinedione class. It is used to treat type 2 diabetes mellitus in adults.

According to the label, each tablet contains 8 milligrams of rosiglitazone maleate. The product is available in various strengths and formulations, including tablets and oral suspension.

The recommended dosage for Avandia varies depending on the patient's age, weight, and other factors. The typical starting dose for adults is 2-4 mg per day, taken once daily.

There are some warnings and concerns associated with Avandia:

  1. Increased risk of heart failure: Rosiglitazone has been linked to an increased risk of heart failure, particularly in patients with pre-existing heart conditions.
  2. Fracture risk: Avandia may increase the risk of bone fractures, especially in postmenopausal women and older adults.
  3. Macular edema: There have been reports of macular edema (a condition that causes vision loss) associated with Avandia use.

As for prices, they can vary depending on the country, pharmacy, and availability. In the United States, the wholesale price of Avandia tablets was around $30-$40 per 100-count bottle in 2022. However, please note that prices may have changed since then.

Regarding health-related disclaimers, there is a boxed warning for Avandia related to an increased risk of heart failure and macular edema. This is specific to the medication itself, as it's a consumable product.

If you or someone you know is taking Avandia, it's essential to consult with a healthcare professional for personalized advice and guidance.

How often it is looked up

Today
1
Last 7 days
8
Last 30 days
31
All time
240

Comments 0

No comments yet. Be the first to share your thoughts!